Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Joel Neal
With
Primary Objective: For cohort A and Cohort C, to determine the central nervous system (CNS) disease control rate (number of patients with stable disease or partial response or complete response / total number of treated patients) at 12 weeks following treatment with etirinotecan pegol in patients with advanced non-small cell lung cancer (NSCLC) or with metastatic brain cancer (mBC) with refractory brain metastases Secondary Objectives: Cohorts A and C: * To measure the overall disease control rate and response rate for patients receiving study therapy * To measure the systemic (non-CNS) disease control rate and response rate for patients receiving study therapy * To observe the progression free survival of the study population * To observe the overall survival of the study population Cohort B: • To observe CNS and systemic disease control in small cell lung cancer (SCLC) Cohorts A, B and C: • To determine the safety profile of etirinotecan pegol
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted